Trial reportClinical research in cardiology : official journal of the German Cardiac Society2011
Ivabradine for the treatment of stable angina pectoris in octogenarians.
Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: results of 48-month study.Clinical research in cardiology : official journal of the German Cardiac Society · 2012Trial
- The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina.Clinical research in cardiology : official journal of the German Cardiac Society · 2012Trial
- Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study.Clinical research in cardiology : official journal of the German Cardiac Society · 2012Trial
- Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2011Trial
- Effectiveness and Impact on Adherence of a New Fixed-Dose Combination of Ivabradine and Metoprolol in a Wide Range of Stable Angina Patients in Real-Life Practice.Cardiology and therapy · 2019Article
- Novel drugs for heart rate control in heart failure.Heart failure reviews · 2018Review
- Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention.Clinical drug investigation · 2017Review
- Review
- Ivabradine: potential clinical applications in critically ill patients.Clinical research in cardiology : official journal of the German Cardiac Society · 2013Review
- Ivabradine: an intelligent drug for the treatment of ischemic heart disease.Molecules (Basel, Switzerland) · 2012Review
- Prognostic relevance of heart rate at rest for survival and the quality of life in patients with dilated cardiomyopathy.Clinical research in cardiology : official journal of the German Cardiac Society · 2012Article
- Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study.Clinical research in cardiology : official journal of the German Cardiac Society · 2012Article
- [New agents for the therapy of angina pectoris].Der Internist · 2011Review
- Role of ivabradine in management of stable angina in patients with different clinical profiles.Open heartReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn patients >80 years (octogenarians), there is an increased incidence of bradycardia due to age-related alteration of the sinus node, AV node, and the conduction system. Therefore, the treatment of angina pectoris with beta-blockers may be limited by bradycardia. The REDUCTION multicenter study evaluated the efficacy of ivabradine in stable angina pectoris in everyday practice. This subgroup analysis evaluated the efficacy and safety of ivabradine in octogenarians.
methodsA total of 4,954 patients were included in the REDUCTION study for treatment of stable angina pectoris. This group included 382 octogenarians (mean age 83 ± 2.9 years) who were followed up over 4 months. Patients were treated with ivabradine in flexible doses (2.5, 5, or 7.5 mg bid). Heart rate (HR), angina pectoris attacks, nitrate consumption, overall efficacy, and tolerance were evaluated.
resultsAfter 4 months of treatment with ivabradine, HR was reduced by 12.0 ± 12.0 bpm from 83.0 ± 15.4 to 71.0 ± 10.1 bpm (p < 0.0001). Angina pectoris attacks were reduced from 3.0 ± 4.6 to 0.8 ± 1.8 per week (p < 0.0001). Consumption of nitrates decreased from 4.2 ± 5.1 to 1.2 ± 2.7 (p < 0.0001). Four patients reported suspected adverse drug reactions. In one patient a syncope occurred. There was no symptomatic bradycardia reported. Efficacy and tolerance were assessed as 'very good/good' for 95 and 99%.
conclusionsThe results demonstrate that ivabradine efficiently reduces HR, number of angina attacks, and nitrate consumption in octogenarian patients. The treatment was safe and well tolerated without relevant bradycardia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.